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Purpose: Historically, it was thought that hemorrhagic complications were increased 
with transrectal ultrasound-guided prostate biopsies (TRUS biopsy) of patients receiv-
ing anticoagulation/antiplatelet therapy. However, the current literature supports the 
continuation of anticoagulation/antiplatelet therapy without additional morbidity. We 
assessed our experience regarding the continuation of anticoagulation/antiplatelet 
therapy during TRUS biopsy.
Materials and Methods: A total of 91 and 98 patients were included in the anti-
coagulation/antiplatelet (group I) and control (group II) groups, respectively. Group I 
subgroups consisted of patients on monotherapy or dual therapy of aspirin, warfarin, 
clopidogrel, or low molecular weight heparin. The TRUS biopsy technique was stand-
ardized to 12 cores from the peripheral zones. Patients completed a questionnaire over 
the 7 days following TRUS biopsy. The questionnaire was designed to assess the pres-
ence of hematuria, rectal bleeding, and hematospermia. Development of rectal pain, 
fever, and emergency hospital admissions following TRUS biopsy were also recorded. 
Results: The patients’ mean age was 65 years (range, 52 to 74 years) and 63.5 years 
(range, 54 to 74 years) in groups I and II, respectively. The overall incidence of hema-
turia was 46% in group I compared with 63% in group II (p=0.018). The incidence of 
hematospermia was 6% and 10% in groups I and II, respectively. The incidence of rectal 
bleeding was similar in group I (40%) and group II (39%). Statistical analysis was con-
ducted by using Fisher exact test.
Conclusions: There were fewer hematuria episodes in anticoagulation/antiplatelet 
patients. This study suggests that it is not necessary to discontinue anticoagu-
lation/antiplatelet treatment before TRUS biopsy.
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INTRODUCTION
Transrectal ultrasound-guided prostate biopsy (TRUS bi-
opsy) is performed to obtain systematic biopsies for histo-
logical examination in patients with suspected prostate 
carcinoma. However, subjecting men to TRUS biopsy can 
cause significant morbidity. The procedure may be compli-
cated by sepsis in 0.5% of patients and by hemorrhagic com-
plications, which are much more common (hematuria, 39 
to 44%; rectal bleeding, 17 to 27%; and hematospermia, 12 
to 16%). These complications tend to be minor and self-lim-
iting [1,2].
There have been historical concerns regarding perform-
ing TRUS biopsy for patients on anticoagulation or anti-Korean J Urol 2012;53:234-239
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TABLE 1. The subgroups of anticoagulation/antiplatelet patients
(group I)
Type  No. of patients (%) (n=88) 
Aspirin alone  52 (59) 
Warfarin alone  18 (21)
Clopidogrel alone    3 (3)
Therapeutic LMWH    1 (1)
Aspirin and warfarin    4 (5)
Aspirin and clopidogrel 10 (11)
LMWH, low molecular weight heparin.
TABLE 2. Patient demographics of both groups 
Group I  Group II 
            Variable
(n=88) (n=95) 
Mean age (yr)        65 (52-74)  63.5 (54-74) 
Median PSA, ng/dl (range)       7.9 (4.5-12)     7.8 (4.3-12)
Median prostate volume,        44 (25-75)     46 (30-85) 
  cc
3 (range) 
Median INR (range)  2.352 (2-2.7)  NA
PSA, prostate-specific antigen; INR, international normalized 
ratio; NA, not available.
platelet therapy owing to bleeding complications [3,4]. The 
current practice with regard to the discontinuation of anti-
coagulation or antiplatelet therapy prior to TRUS biopsy 
varies widely among clinicians, with 52% of radiologists 
and 27% of urologists terminating antiplatelet (aspirin) 
therapy before TRUS biopsy and 95% of radiologists and 
84% of urologists stopping anticoagulation (warfarin) be-
fore TRUS biopsy [5]. However, the literature regarding 
bleeding complications following TRUS biopsy is limited. 
The aim of this prospective study was to assess our expe-
rience regarding the continuation of anticoagulation/anti-
platelet therapy during TRUS biopsy and to compare this 
prospectively with patients not on anticoagulation/anti-
platelet therapy. We sought to assess the previous findings 
of the safety of aspirin and warfarin in patients undergoing 
TRUS biopsy and to document for the first time the effects 
of clopidogrel in these patients.
MATERIALS AND METHODS
Data were collected on patients who were referred for 
TRUS biopsy on the basis of elevated prostate-specific anti-
gen (PSA), an abnormal digital rectal examination, or clin-
ical suspicion. Patients were divided into 2 groups, and a 
total of 88 patients on anticoagulation/antiplatelet ther-
apy (group I) were included. The subgrouping of group I 
consisted of patients on monotherapy of aspirin, warfarin, 
clopidogrel, or low molecular weight heparin (LMWH) and 
patients on dual therapy of aspirin and warfarin or clopi-
dogrel (Table 1). The dosage of aspirin and clopidogrel was 
75 mg daily. The medical indications for patients on anti-
coagulation/antiplatelet therapy are listed in Table 1. 
The control group (group II) of 95 patients who were not 
on anticoagulation or antiplatelet therapy was included for 
comparative analysis. The demographics of both groups, 
including PSA, prostate volumes, and international nor-
malized ratio (INR), are listed in Table 2. A prospective 
comparative analysis was performed between the groups. 
In group I, patients were advised not to discontinue their 
anticoagulation/antiplatelet therapy prior to TRUS bio-
psy. All participants received a detailed information leaflet 
explaining the procedure before undergoing the biopsy. 
The TRUS biopsy technique was standardized to 12 cores 
with an 18-gauge needle from the peripheral zones. A sin-
gle dosage of 400 mg oral ofloxacin and 80 mg intravenous 
gentamicin was given before the procedure. The prostate 
was infiltrated with 10 ml of 1% lidocaine as a local anes-
thetic at the base of each lateral lobe with a 16-gauge spinal 
needle before TRUS biopsy as per the protocol [6]. A total 
of 200 mg of oral ofloxacin was also prophylactically pre-
scribed to all patients for the evening of TRUS biopsy and 
the following morning. 
All patients undergoing the TRUS biopsy completed a 
questionnaire over the 7 days following the biopsy (Fig. 1). 
This questionnaire examined the presence of hematuria, 
rectal bleeding, and hematospermia. Associated symp-
toms such as rectal pain and fever were also included. 
Patients were also asked to comment on whether they 
needed analgesia or general practitioner or hospital visits. 
Also included was information regarding the type of anti-
coagulants or antiplatelets used, known bleeding disorder, 
INR levels, and prostate volumes. A space for additional 
comments by the patient was provided, and relevant com-
ments were taken into consideration. Upon return of the 
questionnaire, all information was entered into an elec-
tronic database and subsequently analyzed. 
1. Statistical analysis
Statistical analysis was conducted by using the Fisher ex-
act test, and a value of ＜0.05 was considered statistically 
significant. Statistical analysis was performed by using 
StataCorp LP ver. 10 (College Station, TX, USA). 
RESULTS
Responses from group I (88 patients) and group II (95 pa-
tients) were analyzed. The mean patient age was 65 years 
(range, 52 to 74 years) and 63.5 years (range, 54 to 74 years) 
in groups I and II, respectively. The overall incidence of 
hematuria was 40/88 patients (46%) in group I compared 
with 60/95 patients (63%) in group II (p=0.018). Additio-
nally, the incidence of hematospermia was 5/88 patients 
(6%) and 9/95 patients (10%) in groups I and II, respectively 
(Table 3). 
In contrast, the incidence of rectal bleeding was similar 
in group I (35/88 patients, or 40%) and group II (37/95 pa-
tients, or 39%) (Table 3). 
The occurrence of rectal pain and the development of fe-Korean J Urol 2012;53:234-239
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FIG. 1. Patients questionnaire of transrectal ultrasound prostate biopsy.
ver after TRUS biopsy were also examined in this study. 
In group I, 5/88 patients (6%) developed rectal pain follow-
ing the procedure compared with 8/95 patients (8%) in 
group II. Similar findings were observed in relation to the 
development of fever after TRUS biopsy (5/88, or 6%, and 
8/95, or 8%, in groups I and II, respectively) (Table 3). 
Only 3 of 5 patients in group I who developed fever after 
TRUS biopsy visited their general practitioner and were 
subsequently prescribed antibiotics as appropriate in com-
parison with 4 of 8 patients in group II. The symptoms of 
rectal pain and fever in the remaining patients were 
self-limiting and did not require hospitalization. No pa-
tients in either group developed overwhelming urosepsis. 
In group I, 2 of 88 patients (2.3%) required acute hospital 
admission with clot retention secondary to frank hema-
turia following TRUS biopsy. In group II, 1 of 95 patients 
(1%) sought medical attention with clot retention secon-
dary to frank hematuria after TRUS biopsy. 
In group I, one patient was on dual therapy of aspirin and 
clopidogrel for drug-eluting coronary stents, whereas the 
second patient was on warfarin alone (INR, 2.5) for atrial 
fibrillation. These patients were assessed, catheterized, 
and admitted to the hospital. The hemoglobin level of these 
patients was 9.4 g/dl (dropped from 11 g/dl at baseline) and 
10 g/dl (dropped from 12 g/dl at baseline) in the first and 
second patients, respectively. Computerized tomography Korean J Urol 2012;53:234-239
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TABLE 3. The overall incidence of complications in both groups 
Finding
Group I 
(n=88)
Group II 
(n=95) 
p-value
Hematuria
Rectal bleeding
Hematospermia 
Rectal pain
Transient fever
a
Emergency admission 
Significant sepsis 
40 (46)
35 (40)
5 (6)
5 (6)
5 (6)
2 (2)
Nil
60 (63)
37 (39)
  9 (10)
8 (8)
8 (8)
1 (1)
Nil
0.018
1.000
0.410
0.517
0.517
0.609
Values are presented as number (%).
p-value＜0.05 considered statistically significant (Fisher exact 
test).
a: Transient fever but not documented infection.
with intravenous contrast showed normal findings of the 
upper urinary tracts in both patients. Both patients were 
discharged well. One patient in group II, however, pre-
sented with clot retention following TRUS biopsy with he-
moglobin of 10.2 g/dl and was managed in a similar fashion 
at both the emergency and ward levels. In both patients, 
the hematuria resolved after catheterization and no addi-
tional treatment or blood transfusion was required. This 
patient was also given prophylactic antibiotics (oral dosage 
of 400 mg twice daily of ciprofloxacin).
DISCUSSION
TRUS biopsy is the procedure of choice for diagnosing pros-
tate cancer and is performed as an outpatient procedure. 
In some centers, it is common to discontinue antiplatelet 
and anticoagulant medications. Patients may need to be 
started on bridging therapy such as intravenous heparin 
infusion before TRUS biopsy to minimize cardiovascular 
or cerebral thrombotic complications [7].
There is evidence in the literature that there is a risk of 
increased cardiovascular or cerebral events associated 
with stopping antiplatelet agents. Current guidelines rec-
ommend that all patients suffering from coronary artery 
disease should receive daily aspirin therapy to reduce the 
risk of thromboembolic events such as stroke, myocardial 
infarction, and death, which is reduced by approximately 
25% in patients with underlying cardiovascular disease 
[8]. It is also estimated that the discontinuation of anti-
platelet therapy may precede up to 10.2% of acute car-
diovascular syndromes. The time interval between dis-
continuation and acute cerebral events was 14.3±11.3 
days, 8.5±3.6 days for acute coronary syndromes, and 
25.8±18.1 days for acute peripheral arterial syndromes [3]. 
Moreover, in patients undergoing coronary stent in-
sertion, the addition of clopidogrel to daily aspirin therapy 
is advocated for at least 1 month in the case of bare metal 
stents, 3 to 6 months for drug-eluting stents, and ideally 
for up to 1 year [9]. This combination has been shown to sig-
nificantly reduce the incidence of ischemic cardiovascular 
events in patients with coronary stents [10,11]. 
Although antiplatelet therapy is commonly used for the 
primary prevention of atherothrombotic disease, it in-
creases the risk of major gastrointestinal and intracranial 
bleeding by approximately 1.7- to 2.1-fold [12]. However, 
the absolute increase in risk of major bleeding is small, re-
quiring 769 patients to be treated for 1 year to induce one 
additional major bleeding event [12]. Conversely, adding 
clopidogrel on top of daily aspirin therapy further increases 
the risk of bleeding, although combined aspirin and clopi-
dogrel therapy has not been associated with increased risk 
of fatal or intracranial hemorrhage [12]. In surgical set-
tings, it is believed that excessive bleeding induced by anti-
platelet agents may result in surgical morbidity or 
mortality. In recent studies, the bleeding and transfusion 
rate following coronary artery bypass grafting was in-
creased by 50% when combined clopidogrel and aspirin 
therapy was continued [13,14]. The practice of withholding 
antiplatelet agents 7 to 10 days before surgery to prevent 
excessive bleeding is widespread [15,16]. It is also known 
that many urology patients will be on long-term, low-dose 
aspirin, which is perhaps self-prescribed or prescribed by 
their general practitioner, usually as a prophylactic treat-
ment for cardiovascular disease. 
In a prospective study by Cahill et al. [17], 51 healthy vol-
unteers were randomly assigned into 3 groups, each receiv-
ing a daily dosage of aspirin 75 mg, aspirin 300 mg, or place-
bo for 14 days. The specific platelet function test (PFA-100) 
was used to monitor platelet function before and after 
therapy. This study demonstrated that the duration of in-
creased bleeding tendency after discontinuation of aspirin 
persisted up to 5 days. The study concluded that aspirin 
therapy should be discontinued 5 days before elective 
surgery. This should allow clinicians and surgeons to mini-
mize the risks of stopping aspirin without increasing the 
risk of excessive perioperative bleeding [17].
Go et al. [18] reported a 50% reduction in the risk of ische-
mic stroke and peripheral embolism in known paroxysmal 
atrial fibrillation when patients were receiving warfarin. 
The authors stated, “Anticoagulation was associated with 
nearly a doubling in the relative rate of intracranial hae-
morrhage, but the additional absolute risk of intracranial 
haemorrhage on anticoagulation was low.” Go et al. [18] al-
so observed no significant increase in the rate of non-intra-
cranial major hemorrhage on warfarin [18]. 
A recent survey from the United Kingdom demonstrated 
a significant variation in practice with regards to pre- and 
postoperative management of clopidogrel in patients un-
dergoing urological procedures. The majority of urologists 
stopped clopidogrel agents before TRUS biopsy (90.6%). 
Furthermore, 43% of urologists did not routinely prescribe 
bridging therapy after discontinuing clopidogrel, and 
92.8% of urologists felt evidence-based guidelines on clopi-
dogrel use during the perioperative period would be useful 
[19]. 
Additionally, there appears to be significant variation in 
practice among orthopedic departments in the United Korean J Urol 2012;53:234-239
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Kingdom, with only 43.6% having a policy of discontinuing 
clopidogrel in patients before surgery for femoral neck 
fractures. This compares with 37.3% of orthopedic depart-
ments having a policy of stopping aspirin and 97.3% stop-
ping warfarin before neck or femur surgery. These studies 
highlight the need for evidence-based guidelines for the 
perioperative management of patients on aspirin, warfar-
in, and clopidogrel in surgical settings [19,20]. 
Connor and Wingate [5] surveyed 91 radiology depart-
ments and 138 urology departments who perform prostate 
biopsies in the United Kingdom and found a wide variation 
in practice. In that study, 52% of radiologists and 27% of 
urologists reported terminating aspirin 5 to 12 days before 
TRUS biopsy. 
A prospective study to determine whether low-dose as-
pirin increases morbidity after 6-core TRUS biopsy was re-
cently performed [21]. In this cohort study, 36 patients 
were taking aspirin before TRUS biopsy compared with 
177 patients who were not taking aspirin before TRUS 
biopsy. This study demonstrated no statistically signifi-
cant difference in the incidence of hematuria or overall 
bleeding after TRUS biopsy between the group on aspirin 
and the group not on aspirin. In our study, 12-core TRUS 
biopsy was performed on all patients as compared with 
6-core TRUS biopsy in Maan’s study [21]. In our study, the 
incidence of hematuria was less at 46% in group I compared 
with 63% in group II (p=0.018). The incidence of hema-
tospermia was 6% and 10% in groups I and II, respectively. 
More recently, strong evidence has appeared in the cur-
rent literature to support continuation of anticoagulation/ 
antiplatelet therapy without additional morbidity [5,21- 
24]. By contrast, Halliwell et al. [22] compared 387 patients 
on aspirin versus 731 patients not on antiplatelet or anti-
coagulation therapy (control). In Halliwell’s study [22], the 
incidence of hematuria and rectal bleeding was higher in 
the aspirin users than in the control group (72% vs. 61%, 
p＜0.01, and 21% vs. 13%, p＜0.001, respectively), but 
there were no significant differences in hematospermia. In 
addition, severe bleeding was very uncommon in both 
groups and no patients required intervention for bleeding 
complications [22].
Another comparative study by Giannarini et al. [23] re-
ported on patients receiving aspirin (n=67) while under-
going 10-core TRUS biopsy. The overall bleeding rate in the 
aspirin group was not significantly higher at 78.5% than 
the 81.5% in the control group (non-aspirin-users). Gian-
narini et al. [23] concluded that no significant bleeding dif-
ference existed for hematuria, rectal bleeding, or hema-
tospermia. 
Ihezue et al. [24] evaluated the morbidity of 49 patients 
on warfarin therapy undergoing TRUS biopsy (mean INR, 
2.2). The incidence of hematuria was 36.7% and 60.2% in 
the warfarin and control groups, respectively. In addition, 
the incidence of hematospermia was 8.2% and 21% in the 
warfarin and control groups, respectively. The incidence of 
rectal bleeding was slightly higher in the warfarin group 
at 14.3% than the 13% in the control group. 
In our study, there was no statistical difference in the oc-
currence of rectal bleeding in either group. In addition, nei-
ther group of patients experienced significant rectal bleed-
ing complications. In addition, patients in group I experi-
enced fewer hematuria episodes than did the control group. 
We are unable to explain this; however, it could also be ar-
gued that, because people receiving anticoagulants are ac-
customed to a tendency to bleed easily, they might view 
their post-biopsy bleeding with less concern than would 
those not receiving anticoagulant therapy. Hence, a great-
er percentage of the control group would report hematuria 
and hematospermia. This may not be the case, however, be-
cause all patients in both groups had a discussion with the 
doctor who performed the TRUS biopsy, who requested 
that they record any episodes of bleeding, however small. 
In the urological setting, the discontinuation of clopidog-
rel before TRUS biopsy is widely practiced among urolo-
gists in the United Kingdom [19]. The clinical application 
of the dual therapy of aspirin and clopidogrel is ideally pre-
scribed for patients undergoing coronary stenting for up to 
1 year after implantation [9]. Although this combination 
has been shown to significantly reduce the incidence of is-
chemic cardiovascular events, adding clopidogrel on top of 
daily aspirin therapy further increases the risk of bleeding 
[12]. In our study, TRUS biopsy was performed on 13 pa-
tients (15%) receiving clopidogrel (3 receiving clopidogrel 
alone and 10 receiving clopidogrel and aspirin). Although 
four patients in group I were on dual therapy of aspirin and 
warfarin for atrial fibrillation, none of the patients devel-
oped a significant bleeding complication. One would expect 
an increased incidence of bleeding complications in these 
subgroups. One patient on dual therapy of clopidogrel and 
aspirin for drug-eluting coronary stents developed clot re-
tention following TRUS biopsy and required hospitali-
zation.
CONCLUSIONS
The results of this multigroup study suggest that it is safe 
to continue with anticoagulation/antiplatelet treatment 
before TRUS biopsy. In addition, the results highlight the 
urgent need for large randomized trials to systematically 
evaluate the safety of continuation of anti-
coagulation/antiplatelet therapy in patients undergoing 
TRUS biopsy, particularly in relation to clopidogrel. This 
is also the first discussion of the effects of clopidogrel in pa-
tients undergoing TRUS biopsy. Future research should fo-
cus on increasing the sample size to increase the statistical 
power of the study. Another research facet should be di-
rected to evaluating the radiological aspects of the pro-
static changes following TRUS biopsy in patients receiving 
anticoagulant/antiplatelet therapy. 
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